Madrigal Pharmaceuticals, Inc. MDGL 深 滬
等待開盤 08-21 09:30:00 美东时间
519.09
-21.070
-3.90%
華盛通- 最 高539.73
- 今 開537.01
- 成交量 26.45万股
- 最 低 518.65
- 昨 收 540.16
- 總市值 119.93亿
- 52周最高 615.00
- 市盈率 靜 --
- 換手率 1.14%
- 52周最低 393.605
- 委 比 93.18%
- 總股本 2310.41万
- 歷史最高 615.00
- 量 比 0.95
- 振 幅 3.90%
- 歷史最低 5.25
- 每 手 1
- 風險率 51.27%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多This Hedge Fund Portfolio Shrinks 17% as Billionaire Bets Big on Gold
John Paulson‘s hedge fund trimmed its equity book to $2.58 billion in the second quarter, down from $3.11 billion in Q1, according to the firm’s 13F filed on Friday. The number of disclosed positions shrank to eight from nine as the billionaire investor exited two names entirely. GOOGL stock is mov...
08-18 01:12
Madrigal Pharmaceuticals Adds Renowned Leader to Board
Madrigal Pharmaceuticals ( ($MDGL) ) has shared an update. On August 11, 2026, ...
08-12 20:48
Madrigal Appoints John C. Reed, M.D., Ph.D., to its Board of Directors
Madrigal Pharmaceuticals appoints John C. Reed, M.D., Ph.D., to its Board of Directors. Dr. Reed, currently Executive Vice President of Innovative Medicine, Research & Development at Johnson & Johnson, brings extensive experience in advancing innovative medicines and leading global R&D strategies. His expertise will support Madrigal's growth in metabolic dysfunction-associated steatohepatitis (MASH) therapeutics, particularly with its approved dr...
08-12 12:00
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
Madrigal Pharmaceuticals granted equity awards to 10 new non-executive employees on August 1, 2026, under its 2025 Inducement Plan. The awards consist of 4,263 time-based restricted stock units, vesting over four years contingent on continued employment. Madrigal is a biopharmaceutical company focused on treating metabolic dysfunction-associated steatohepatitis (MASH) with its approved drug, Rezdiffra, and is conducting further trials for its use...
08-06 20:05
This Palantir Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page. Leerink Partners analyst Jonathan Chang upgraded Replimune Group Inc (NASDAQ:REPL) from Market Pe...
08-04 19:46
美股大行评级 | 潜在涨幅3586.64%！HC Wainwright上调Enlivex目标价至80美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Enlivex"买入"评级，目标价从20美元升至80美元；Canaccord Genuity：维持Pharming Group NV Sponsored ADR"买入"评级，目标价从37美元升至38美元
08-04 11:45
Madrigal Pharmaceuticals shares are trading lower. The company reported Q2 financial results.
Madrigal Pharmaceuticals shares are trading lower. The company reported Q2 financial results.
07-30 20:56
Madrigal Pharmaceuticals Q2 EPS $(1.99) Beats $(2.50) Estimate, Sales $364.252M Beat $353.178M Estimate
Madrigal Pharmaceuticals (NASDAQ:MDGL) reported quarterly losses of $(1.99) per share which beat the analyst consensus estimate of $(2.50) by 20.4 percent. This is a 4.74 percent decrease over losses of $(1.90) per share from the same period last year. The company reported quarterly sales of $364.25...
07-30 19:03
美股大行评级 | 最高1400美元！花旗、大小摩8家大行上调希捷科技目标价；大行集中调整目标价：康宁、科斯塔、思佳讯遭下调，PayPal、Visa、可口可乐、赛莱默获上调
今日重点评级关注：古根海姆：维持ProMIS Neurosciences"买入"评级，目标价从35美元升至69美元；BTIG：维持Cullinan Therapeutics"买入"评级，目标价从38美元升至39美元
07-30 11:45
Madrigal Pharmaceuticals Reports Second-Quarter 2026 Financial Results and Provides Corporate Updates
Madrigal Pharmaceuticals reported strong second-quarter 2026 results with Rezdiffra net sales of $364.3 million, up 71% year-over-year. The company surpassed 49,000 patients on Rezdiffra, reflecting strong adoption. They strengthened IP with 3 new resmetirom patents, including F4c, and initiated Phase 1 trials for MGL-2086, an oral GLP-1 receptor agonist. Cash reserves stood at $838.9 million. The company plans a conference call to discuss result...
07-30 11:00
